ORCHPHARMA
1 call
Concalls & earnings callsOrchid Pharma Limited
Every summarised call, newest first. Latest is Q1 FY27, held 21 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from Operations | ₹304 Cr | approx. 15% | |
| Combined Gross Margin | 33% | approx. 3% points | |
| EBITDA | ₹25 Cr | — | |
| AMS Division Revenue | ₹5 Cr | — |
Latest guidance
- Initial benefits from merger integration initiatives are expected to begin becoming visible in the next financial year.
- Cefiderocol facility commissioning is targeted for December 2026, with validation and initial batches from January to March 2027.
- 7-ACA project aims for commissioning and first commercial batch by March 2027.
- No yearly revenue growth guidance was provided for FY27.
- Exblifep (Enmetazobactam) lifetime sales potential remains $1.1 billion to $2 billion.
- For 7-ACA, long-term utilization guidance is 80% in-house use and 20% third-party sales.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹217.34 Cr-1.5% YoY-2.4% QoQ | ₹20.78 Cr-29.4% YoY-23.7% QoQ | ₹4.10-33.7% YoY-23.6% QoQ |
| Q2 FY25 | ₹222.70 Cr+12% YoY-8.9% QoQ | ₹27.24 Cr+37.6% YoY-7.2% QoQ | ₹5.37+24.9% YoY-7.3% QoQ |
| Q1 FY25 | ₹244.41 Cr+33.6% YoY+12.6% QoQ | ₹29.35 Cr+212.2% YoY-11% QoQ | ₹5.79+213% YoY-15% QoQ |
| Q4 FY24 | ₹217.10 Cr+3.4% YoY-1.6% QoQ | ₹32.96 Cr-44.3% YoY+12% QoQ | ₹6.81-57.8% YoY+10.2% QoQ |
| Q3 FY24 | ₹220.59 Cr+38.1% YoY+11% QoQ | ₹29.43 Cr+287.7% YoY+48.6% QoQ | ₹6.18+232.3% YoY+43.7% QoQ |
Call history
- Q1 FY27Cautious tone
Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.
- Revenue from Operations
- ₹304 Crapprox. 15%
- Combined Gross Margin
- 33%approx. 3% points